Urology Oncology Fellowship
The Urologic Oncology Fellowship Program at Indiana University School of Medicine is a two-year program comprised of one research year followed by one year of clinical fellowship. Consistent with the mission of the Society of Urologic Oncology, the program provides comprehensive training in clinical genitourinary oncology through advanced surgical training, multidisciplinary didactics and clinical/translational research endeavors.
First Year Curriculum
During the first year, fellows participate in clinical, translational and basic science research. Research training covers protocol development and clinical trial design, collaboration and coordination of translational projects with researchers at Indiana University and Purdue University, and health services and outcomes-based study. Basic science research is focused on genetic and translational approaches to the treatment and management of urologic malignancies.
Opportunities to rotate with Department of Urology medical oncology and radiation oncology colleagues are coordinated during the year, and fellows serve as a clinical staff at a county hospital, participating in autonomous resident supervision and teaching. Overall clinical responsibilities during the first year of this fellowship program comprises less than ten percent of the fellow’s time. The remaining time is protected for research and academic study.
Fellows are encouraged to present abstracts at regional and national meetings and contribute to peer-reviewed publications. Fellows are responsible for leading a weekly multidisciplinary cancer conference.
The second year of this fellowship is dedicated to clinical training in the operating room. Fellows participate in a wide array of open and minimally invasive surgery procedures performed under the supervision of experienced urologic oncology faculty physicians. The department’s teaching faculty have unparalleled clinical experience in complex oncologic and reconstructive surgery and are recognized globally for surgical expertise in testicular and advanced bladder cancer.